SlideShare ist ein Scribd-Unternehmen logo
1 von 10
Downloaden Sie, um offline zu lesen
An Introduction to PARSORTIX

Presented by:
Andrew Newland, Chief Executive
Shane Booth, CEO, Parsortix

7 October 2011
Major medical diagnostic development for ANGLE


Parsortix
Patented technology for
separating rare cells from blood

Forward-Looking Statements
This presentation and the associated commentary contains certain forward-looking statements
based on current expectations, forecasts and assumptions that involve significant risks and
uncertainties. These statements are based on information currently available to the Company; and
ANGLE / Parsortix's actual results could differ materially from those stated or implied, due to risks
and uncertainties associated with its business.

Forward-looking statements include statements regarding expectations, beliefs, intentions or
strategies regarding the future and can be identified by forward-looking words such as “potential”,
“target”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”,
and “would” or similar words. ANGLE assumes no obligation to update the information included in
this presentation, whether as a result of new information, future events or otherwise.

                                                                                 © ANGLE plc 2011   Page 2
Market for circulating tumour cell (CTC) separation device


  Use of CTC cell counting (simple product) for:
  −   Research product (does not need regulatory approval)
  −   Monitoring patient response to chemotherapy
  −   Monitoring patients in remission to identify CTC ahead of secondary tumours

  1.2 million new cancer patients per annum in the US market alone*
  −   Each patient may need to be monitored over 30 times

  Target: potential therapeutic application for a product recovering cells
  −   A pressing need for CTC recovery in relation to lung, pancreatic, and colo-rectal
      cancers as tumour access for biopsy difficult
  −   These cancers account for approximately one third of the total number of cases
      annually in the US

  ANGLE may develop the product initially cancer by cancer




                                                           *Source : US National Cancer Institute in 2010
                                                                               © ANGLE plc 2011   Page 3
Parsortix: separation cassette schematic

                                             Cassette components




                                           Fully assembled cassette




                                                Cassette housing




                                                  © ANGLE plc 2011    Page 4
Captured cells: whole blood control and spiked with SK-Br-3




Control




Spiked with
breast cancer
cells




                                                           © ANGLE plc 2011   Page 5
Chromogenic staining of SK-Br-3 cells




Stained breast
Cancer cells




Visual ID
breast cancer
cells




                          Identified cells marked using cytokeratin-18
                                                                         © ANGLE plc 2011
Development Plan


   Finalise work on characterising the separation device including flow and
   volume capability

   Finalise market requirements for device

   Optimise design of separation device (next generation)

   Establish collaboration with cancer research centre(s)

   Separation of CTCs from cancer patient blood

   Beta test next generation separation device

   Final design of separation device

   Manufacture in quantity

   Initiate sales for research purposes

Target for completion mid 2012

                                                                    © ANGLE plc 2011   Page 7
Newsflow potential

Quarter ended        31-Oct-11           31-Jan-12           30-Apr-12            31-Jul-12          31-Oct-12        31-Jan-13         30-Apr-13           31-Jul-13


                                                                                                             Continue and expand sales for research purposes

                                      Establish           Optimise             Initiate sales
                                      collaborative       separation           for research         Comparative studies to support FDA and CE Mark
                                      research with       cassette and         purposes                               submission
                                      leading Cancer      consumable                                                                                     FDA/CE Mark
                                      Centres in the US   design                                                                                         approval
                   Validation of
                                      and UK
                   initial findings
Parsortix                                                 Advance
                                                          discussions with
                   (completed)
                                                          Corporate Partners
                                                                                Consider joint                                       Corporate deal/
                                      Capture CTCs in
                                                                                development                                          distribution
                                      cancer patient      Establish world
                                                                                programmes                                           partner finalised Target for
                                      blood               leading Scientific
                                                                                with Corporate                                                         clinical product
                                                          Advisory Board
                                                                                Partners                                                               launch and sales




Acolyte            Completion of      Judgement on        ANGLE decision on    Potential for 3M
Biomedica          Acolyte case       Acolyte case        case against 3M      settlement




                                      Launch of           Completion of
                                                                                                  Potential for
Geomerics                             Battlefield3 and    milestone 3 for
                                                                                                  trade sale
                                      Need for Speed      major corporate




                                                                                                  Potential for                                          Potential for
                                                          Retrospective                                                              Prospective study
Novocellus                                                                                        milestone                                              product sales
                                                          study results                                                              results
                                                                                                  payments                                               and royalties




             = key value triggers


                                                                                                                                               © ANGLE plc 2011           Page 8
Near-term commercial potential

 Target sales launch of product for research purposes mid 2012
   − No requirement for regulatory approval
   − Immediate market potential
   − Astra Zeneca 20,000 separations p.a. with one research lab
   − Early sales potential $25m p.a.

 Target FDA approval of product for clinical use mid 2013

 Clinical market for “simple counting product” estimated at $4bn p.a. in US
 market alone

 Gross margin in excess of 75%

 Significant corporate interest for collaboration with more complex products


The key is a simple, effective product



                                                                  © ANGLE plc 2011   Page 9
Legal disclaimer

The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment
(without notice), verification and completeness.

 This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on,
directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to
recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether
orally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of it
may be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or the
Republic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation S
promulgated under the United States Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not
constitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in the
Company. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user should
inform themselves about and observe any applicable legal requirements. Neither this document nor any part of this document
should be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic
transmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada,
Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or to
any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside the
United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution
could result in violation of the laws of such countries.

This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to
purchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for
any purpose whatsoever on the information, representation or opinions.

 This document should not be considered as the giving of investment advice by the Company or any of its shareholders,
directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own
independent assessment of the Company after making such investigations and taking such advice as may be deemed
necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of
subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters.

Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the
accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept
any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or
otherwise arising in connection therewith.



                                                                                                        © ANGLE plc 2011    Page 10

Weitere ähnliche Inhalte

Ähnlich wie Angle parsortix presentation 07oct11

Santander latin america energy & materials london, october 2009
Santander latin america energy & materials   london, october 2009Santander latin america energy & materials   london, october 2009
Santander latin america energy & materials london, october 2009Braskem_RI
 
Santander latin america energy & materials london, october 2009
Santander latin america energy & materials   london, october 2009Santander latin america energy & materials   london, october 2009
Santander latin america energy & materials london, october 2009Braskem_RI
 
Itau annual brazil conference
Itau annual brazil conferenceItau annual brazil conference
Itau annual brazil conferenceBraskem_RI
 
Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015Matt Sanderson
 
Seamvad - BP_Aug 2012
Seamvad - BP_Aug 2012Seamvad - BP_Aug 2012
Seamvad - BP_Aug 2012shaharpeled
 
OpenERP - Healthcare Industry, Valuedecision
OpenERP - Healthcare Industry, ValuedecisionOpenERP - Healthcare Industry, Valuedecision
OpenERP - Healthcare Industry, ValuedecisionOdoo
 
Smb 13032014 hve jack schalken oncodrone
Smb 13032014 hve jack schalken   oncodroneSmb 13032014 hve jack schalken   oncodrone
Smb 13032014 hve jack schalken oncodroneSMBBV
 
201109 DiagnoCure Corporate presentation
201109   DiagnoCure Corporate presentation201109   DiagnoCure Corporate presentation
201109 DiagnoCure Corporate presentationDiagnoCure
 
Anteo Diagnostics Quarterly Report - (ASX : ADO)
Anteo Diagnostics Quarterly Report - (ASX : ADO)Anteo Diagnostics Quarterly Report - (ASX : ADO)
Anteo Diagnostics Quarterly Report - (ASX : ADO)Matt Sanderson
 
Small GTL Joint Industry Project
Small GTL Joint Industry ProjectSmall GTL Joint Industry Project
Small GTL Joint Industry ProjectCyril Stahl
 
Anteo Technologies Investor Presentation
Anteo Technologies Investor PresentationAnteo Technologies Investor Presentation
Anteo Technologies Investor PresentationMatt Sanderson
 
Article IVD March 2006
Article IVD March 2006Article IVD March 2006
Article IVD March 2006Fabrice Sultan
 
Health Valley 2014: Jack Schalken
Health Valley 2014: Jack SchalkenHealth Valley 2014: Jack Schalken
Health Valley 2014: Jack SchalkenHealth Valley
 
OneMedPlace November Research Report
OneMedPlace November Research ReportOneMedPlace November Research Report
OneMedPlace November Research Reportwww.datatrak.com
 
Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015Matt Sanderson
 
Medvantage Tech Overview
Medvantage Tech OverviewMedvantage Tech Overview
Medvantage Tech Overviewezitizer
 

Ähnlich wie Angle parsortix presentation 07oct11 (20)

Santander latin america energy & materials london, october 2009
Santander latin america energy & materials   london, october 2009Santander latin america energy & materials   london, october 2009
Santander latin america energy & materials london, october 2009
 
Santander latin america energy & materials london, october 2009
Santander latin america energy & materials   london, october 2009Santander latin america energy & materials   london, october 2009
Santander latin america energy & materials london, october 2009
 
Itau annual brazil conference
Itau annual brazil conferenceItau annual brazil conference
Itau annual brazil conference
 
Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015Anteo Diagnostics Research Report November 2015
Anteo Diagnostics Research Report November 2015
 
Inserogen lecture 7 partners
Inserogen lecture 7 partnersInserogen lecture 7 partners
Inserogen lecture 7 partners
 
Seamvad - BP_Aug 2012
Seamvad - BP_Aug 2012Seamvad - BP_Aug 2012
Seamvad - BP_Aug 2012
 
14 announcement 25.08.2011
14 announcement 25.08.201114 announcement 25.08.2011
14 announcement 25.08.2011
 
OpenERP - Healthcare Industry, Valuedecision
OpenERP - Healthcare Industry, ValuedecisionOpenERP - Healthcare Industry, Valuedecision
OpenERP - Healthcare Industry, Valuedecision
 
Smb 13032014 hve jack schalken oncodrone
Smb 13032014 hve jack schalken   oncodroneSmb 13032014 hve jack schalken   oncodrone
Smb 13032014 hve jack schalken oncodrone
 
TopoTarget - Kapitalmarkedsdag marts 2012
TopoTarget - Kapitalmarkedsdag marts 2012TopoTarget - Kapitalmarkedsdag marts 2012
TopoTarget - Kapitalmarkedsdag marts 2012
 
201109 DiagnoCure Corporate presentation
201109   DiagnoCure Corporate presentation201109   DiagnoCure Corporate presentation
201109 DiagnoCure Corporate presentation
 
Anteo Diagnostics Quarterly Report - (ASX : ADO)
Anteo Diagnostics Quarterly Report - (ASX : ADO)Anteo Diagnostics Quarterly Report - (ASX : ADO)
Anteo Diagnostics Quarterly Report - (ASX : ADO)
 
Small GTL Joint Industry Project
Small GTL Joint Industry ProjectSmall GTL Joint Industry Project
Small GTL Joint Industry Project
 
Anteo Technologies Investor Presentation
Anteo Technologies Investor PresentationAnteo Technologies Investor Presentation
Anteo Technologies Investor Presentation
 
Outsourcing
OutsourcingOutsourcing
Outsourcing
 
Article IVD March 2006
Article IVD March 2006Article IVD March 2006
Article IVD March 2006
 
Health Valley 2014: Jack Schalken
Health Valley 2014: Jack SchalkenHealth Valley 2014: Jack Schalken
Health Valley 2014: Jack Schalken
 
OneMedPlace November Research Report
OneMedPlace November Research ReportOneMedPlace November Research Report
OneMedPlace November Research Report
 
Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015Anteo Technologies - New York presentation 2015
Anteo Technologies - New York presentation 2015
 
Medvantage Tech Overview
Medvantage Tech OverviewMedvantage Tech Overview
Medvantage Tech Overview
 

Mehr von ANGLE plc

Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015
Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015
Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015ANGLE plc
 
Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum  Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum ANGLE plc
 
ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015ANGLE plc
 
Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015ANGLE plc
 
Personalised Cancer Care December 2014
Personalised Cancer Care December 2014Personalised Cancer Care December 2014
Personalised Cancer Care December 2014ANGLE plc
 
Shares Investor Evening 29 October 2014
Shares Investor Evening 29 October 2014Shares Investor Evening 29 October 2014
Shares Investor Evening 29 October 2014ANGLE plc
 
The Stock Market Show | 13 September 2014
The Stock Market Show | 13 September 2014The Stock Market Show | 13 September 2014
The Stock Market Show | 13 September 2014ANGLE plc
 
Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014ANGLE plc
 
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...ANGLE plc
 
About the Parsortix System
About the Parsortix SystemAbout the Parsortix System
About the Parsortix SystemANGLE plc
 
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum ANGLE plc
 
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013ANGLE plc
 
ANGLE Annual Report 2013
ANGLE Annual Report 2013ANGLE Annual Report 2013
ANGLE Annual Report 2013ANGLE plc
 
ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13ANGLE plc
 
ANGLE Interim Results 2013 31jan13
ANGLE Interim Results 2013 31jan13ANGLE Interim Results 2013 31jan13
ANGLE Interim Results 2013 31jan13ANGLE plc
 
ANGLE Preliminary Results 2012 26jul12
ANGLE Preliminary Results 2012 26jul12ANGLE Preliminary Results 2012 26jul12
ANGLE Preliminary Results 2012 26jul12ANGLE plc
 
Angle interim results 2012 26jan12
Angle interim results 2012 26jan12Angle interim results 2012 26jan12
Angle interim results 2012 26jan12ANGLE plc
 

Mehr von ANGLE plc (17)

Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015
Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015
Presentation 28 July 2015: Preliminary Results for the year ended 30 April 2015
 
Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum  Presentation 2 July 2015: Proactive Investors Forum
Presentation 2 July 2015: Proactive Investors Forum
 
ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015ANGLE shares investor evening 15 April 2015
ANGLE shares investor evening 15 April 2015
 
Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015Liquid Biopsy 29 January 2015
Liquid Biopsy 29 January 2015
 
Personalised Cancer Care December 2014
Personalised Cancer Care December 2014Personalised Cancer Care December 2014
Personalised Cancer Care December 2014
 
Shares Investor Evening 29 October 2014
Shares Investor Evening 29 October 2014Shares Investor Evening 29 October 2014
Shares Investor Evening 29 October 2014
 
The Stock Market Show | 13 September 2014
The Stock Market Show | 13 September 2014The Stock Market Show | 13 September 2014
The Stock Market Show | 13 September 2014
 
Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014Parsortix non-invasive cancer diagnostics | 3 September 2014
Parsortix non-invasive cancer diagnostics | 3 September 2014
 
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
Liquid biopsy from a simple blood test enabling personalised cancer care | Sh...
 
About the Parsortix System
About the Parsortix SystemAbout the Parsortix System
About the Parsortix System
 
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
ANGLE Presentation 4 February 2014 Shares Cenkos Investor Forum
 
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
ANGLE plc 30 January 2014: Interim Results for the year ended 31 October 2013
 
ANGLE Annual Report 2013
ANGLE Annual Report 2013ANGLE Annual Report 2013
ANGLE Annual Report 2013
 
ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13ANGLE Peliminary Results 2013 31jul13
ANGLE Peliminary Results 2013 31jul13
 
ANGLE Interim Results 2013 31jan13
ANGLE Interim Results 2013 31jan13ANGLE Interim Results 2013 31jan13
ANGLE Interim Results 2013 31jan13
 
ANGLE Preliminary Results 2012 26jul12
ANGLE Preliminary Results 2012 26jul12ANGLE Preliminary Results 2012 26jul12
ANGLE Preliminary Results 2012 26jul12
 
Angle interim results 2012 26jan12
Angle interim results 2012 26jan12Angle interim results 2012 26jan12
Angle interim results 2012 26jan12
 

Kürzlich hochgeladen

concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxLikeways
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 

Kürzlich hochgeladen (20)

concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptxGood Laboratory Practice (GLP) in Pharma-LikeWays.pptx
Good Laboratory Practice (GLP) in Pharma-LikeWays.pptx
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Cone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptxCone beam CT: concepts and applications.pptx
Cone beam CT: concepts and applications.pptx
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 

Angle parsortix presentation 07oct11

  • 1. An Introduction to PARSORTIX Presented by: Andrew Newland, Chief Executive Shane Booth, CEO, Parsortix 7 October 2011
  • 2. Major medical diagnostic development for ANGLE Parsortix Patented technology for separating rare cells from blood Forward-Looking Statements This presentation and the associated commentary contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve significant risks and uncertainties. These statements are based on information currently available to the Company; and ANGLE / Parsortix's actual results could differ materially from those stated or implied, due to risks and uncertainties associated with its business. Forward-looking statements include statements regarding expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “potential”, “target”, “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “should”, “will”, and “would” or similar words. ANGLE assumes no obligation to update the information included in this presentation, whether as a result of new information, future events or otherwise. © ANGLE plc 2011 Page 2
  • 3. Market for circulating tumour cell (CTC) separation device Use of CTC cell counting (simple product) for: − Research product (does not need regulatory approval) − Monitoring patient response to chemotherapy − Monitoring patients in remission to identify CTC ahead of secondary tumours 1.2 million new cancer patients per annum in the US market alone* − Each patient may need to be monitored over 30 times Target: potential therapeutic application for a product recovering cells − A pressing need for CTC recovery in relation to lung, pancreatic, and colo-rectal cancers as tumour access for biopsy difficult − These cancers account for approximately one third of the total number of cases annually in the US ANGLE may develop the product initially cancer by cancer *Source : US National Cancer Institute in 2010 © ANGLE plc 2011 Page 3
  • 4. Parsortix: separation cassette schematic Cassette components Fully assembled cassette Cassette housing © ANGLE plc 2011 Page 4
  • 5. Captured cells: whole blood control and spiked with SK-Br-3 Control Spiked with breast cancer cells © ANGLE plc 2011 Page 5
  • 6. Chromogenic staining of SK-Br-3 cells Stained breast Cancer cells Visual ID breast cancer cells Identified cells marked using cytokeratin-18 © ANGLE plc 2011
  • 7. Development Plan Finalise work on characterising the separation device including flow and volume capability Finalise market requirements for device Optimise design of separation device (next generation) Establish collaboration with cancer research centre(s) Separation of CTCs from cancer patient blood Beta test next generation separation device Final design of separation device Manufacture in quantity Initiate sales for research purposes Target for completion mid 2012 © ANGLE plc 2011 Page 7
  • 8. Newsflow potential Quarter ended 31-Oct-11 31-Jan-12 30-Apr-12 31-Jul-12 31-Oct-12 31-Jan-13 30-Apr-13 31-Jul-13 Continue and expand sales for research purposes Establish Optimise Initiate sales collaborative separation for research Comparative studies to support FDA and CE Mark research with cassette and purposes submission leading Cancer consumable FDA/CE Mark Centres in the US design approval Validation of and UK initial findings Parsortix Advance discussions with (completed) Corporate Partners Consider joint Corporate deal/ Capture CTCs in development distribution cancer patient Establish world programmes partner finalised Target for blood leading Scientific with Corporate clinical product Advisory Board Partners launch and sales Acolyte Completion of Judgement on ANGLE decision on Potential for 3M Biomedica Acolyte case Acolyte case case against 3M settlement Launch of Completion of Potential for Geomerics Battlefield3 and milestone 3 for trade sale Need for Speed major corporate Potential for Potential for Retrospective Prospective study Novocellus milestone product sales study results results payments and royalties = key value triggers © ANGLE plc 2011 Page 8
  • 9. Near-term commercial potential Target sales launch of product for research purposes mid 2012 − No requirement for regulatory approval − Immediate market potential − Astra Zeneca 20,000 separations p.a. with one research lab − Early sales potential $25m p.a. Target FDA approval of product for clinical use mid 2013 Clinical market for “simple counting product” estimated at $4bn p.a. in US market alone Gross margin in excess of 75% Significant corporate interest for collaboration with more complex products The key is a simple, effective product © ANGLE plc 2011 Page 9
  • 10. Legal disclaimer The information and opinions contained in this presentation are provided as at the date hereof and are subject to amendment (without notice), verification and completeness. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published in whole or in part for any purpose. This document is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether orally or in writing, in connection with the Company. Neither this document or any part of this document nor any copy of it may be sent to or taken into the United States of America, Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland, nor may it be distributed to, directly or indirectly, to any US person (within the meaning of regulation S promulgated under the United States Securities Act of 1933, (as amended) (the “US Securities Act”)). This document does not constitute an offer to buy or to subscribe for, or the solicitation of an offer to buy or to subscribe for securities in the Company. To the extent this document is received or used in jurisdictions outside the UK, any such recipient or user should inform themselves about and observe any applicable legal requirements. Neither this document nor any part of this document should be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America (or any of its territories or possessions) Canada, Australia, Japan, the Republic of South Africa or the Republic of Ireland or to any citizens, residents or nationals thereof, or to any corporation, partnership or other entity created or organised under the laws thereof or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Any such distribution could result in violation of the laws of such countries. This document does not constitute or form any part of any offer or invitation or other solicitation or recommendation to purchase any securities in the Company and does not constitute or form part of a prospectus. No reliance may be placed for any purpose whatsoever on the information, representation or opinions. This document should not be considered as the giving of investment advice by the Company or any of its shareholders, directors, officers, agents, employees or advisers. Each party to whom this document is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters. Neither the Company nor any other person makes any guarantee, representation or warranty, express or implied, as to the accuracy, completeness or fairness of the information and opinions contained in this document, nor does the Company accept any responsibility or liability whatsoever for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection therewith. © ANGLE plc 2011 Page 10